Michael Thurn

Michael Thurn

Director/Board Member at NEURIZON THERAPEUTICS LIMITED

Net worth: 127 998 $ as of 31/05/2026

Health Technology
Consumer Services
Health Services

Profile

Michael Thurn is the founder of Marp Therapeutics Pty Ltd. Current positions include Non-Executive Director at Arovella Therapeutics Ltd. starting in 2026, Director at Inmagene Biopharmaceuticals, Director at Impel Neuropharma, and Non-Executive Director at Neurizon Therapeutics Ltd. starting in 2026.
Former roles include Chief Executive Officer at Mimetica Pty Ltd. from 2006 to 2014, Chief Executive Officer at Neurizon Therapeutics Ltd. from 2023 to 2024, Chief Operating Officer & Executive Director at Botanix Pharmaceuticals Ltd. from 2019 to 2020, Managing Director at Spinifex Pharmaceuticals Pty Ltd., Director at Erasca, Inc., Team Leader at Kazia Therapeutics Ltd., Chief Operating Officer at YM BioSciences Australia Pty Ltd., Head-Drug Development at Xenome Ltd., and Senior Toxicologist at Therapeutic Goods Administration.
Education includes a doctorate from the University of Technology Sydney conferred in 1994.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
07/11/2024 2,869,276 ( 0.38% ) 127 998 $ 31/05/2026

Michael Thurn active positions

CompaniesPositionStart
NEURIZON THERAPEUTICS LIMITED Director/Board Member 31/05/2024
AROVELLA THERAPEUTICS LIMITED Director/Board Member 28/04/2026

Former positions of Michael Thurn

CompaniesPositionEnd
NEURIZON THERAPEUTICS LIMITED Chief Executive Officer 23/04/2024
BOTANIX PHARMACEUTICALS LIMITED Chief Operating Officer 26/02/2020
ERASCA, INC. Director/Board Member -
Founder -
Therapeutic Goods Administration
Corporate Officer/Principal -
See the detail of Michael Thurn's experience

Training of Michael Thurn

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

36

1st degree connections

12

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies12

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Health Technology

Therapeutic Goods Administration

Health Technology

Health Services

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!